Tiomolibdate choline - Alexion AstraZeneca Rare Disease/University of Michigan
Alternative Names: ALXN-1840; ATN-224; Bis(choline)tetrathiomolybdate; Bis-choline tetrathiomolybdate; Decuprate; WTX-101Latest Information Update: 05 Nov 2023
At a glance
- Originator University of Michigan
- Developer Alexion AstraZeneca Rare Disease; Attenuon; Cancer Research UK
- Class Antineoplastics; Heavy metals; Neuroprotectants; Small molecules
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
- Discontinued Breast cancer; Hepatolenticular degeneration; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours
Most Recent Events
- 30 Jun 2023 Alexion terminates phase-III trial in Hepatolenticular degeneration (In adolescents, In adults, In the elderly) in in United Kingdom, Turkey, Serbia, Taiwan, Singapore, Russia, Spain, Poland, New Zealand, South Korea, Japan, Israel, Hong Kong, Hungary, Germany, France, Denmark, Czech Republic, Canada, Belgium, Austria, Australia (PO) due to Sponsor decision to terminate the programm (NCT03403205)
- 26 Jun 2023 Alexion terminates phase III trial in Hepatolenticular degeneration (In adolescents, In children) in France, Germany, Japan, South Korea, Poland, Spain, United Kingdom (PO) due to sponsor decision to terminate the program (NCT05047523)
- 21 Jun 2023 Pharmacokinetics data from phase II trial in healthy volunteers presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)